menu
    • menu
    [{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"LinPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Lysine","moa":"Vasopressin receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"LinPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LinPharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LinPharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Lisina

    Menu

    Lisina

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LinPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LinPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lysine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyranda, a Breakthrough Cold Sore Treatment, is Now Available in the U.S.

                            Details : Lyranda (L-lysine) has antiviral effects by blocking the activity of arginine, which promotes the replication of the herpes simplex virus (HSV).

                            Product Name : Lyranda

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            August 28, 2024

                            Lead Product(s) : Lysine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,Everolimus,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Temasek Life Sciences Laboratory

                            Deal Size : $272.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisoto...

                            Details : The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neur...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 05, 2023

                            Lead Product(s) : 177-Lu Edotreotide,Everolimus,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Temasek Life Sciences Laboratory

                            Deal Size : $272.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) i...

                            Details : ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022

                            Details : ITM-11 (n.c.a. 177Lu-edotreotide), as first- or second-line treatment compared to best standard of care for patients with well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Des...

                            Details : ITM-11 is a Targeted Radionuclide Therapy consisting of the high-quality beta-emitting radioisotope, no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the tumor-specific targeting molecule edotreotide.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmace...

                            Details : The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroe...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of N...

                            Details : ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 09, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma

                            Details : The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of N...

                            Details : ITM-11 (177Lu-edotreotide), a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors demonstrated promising results in its trial for the treatment of hard-to-treat tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater...

                            Details : Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and com...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            December 27, 2021

                            Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth